novo nordisk semaglutide clinical trials SURMOUNT-5: Tirzepatide and go head-to-head in battle of weight loss drugs Novo Nordisk's semaglutide aces another

At the 12-month time point, 70.5% of the German dulaglutide users were receiving the 1.5-mg dose, while in the UK the proportion was 79.9%

Your clinician will consider factors including: Your overall health status and comorbidities The degree of obesity and associated health risks Previous history of biliary symptoms The urgency of weight loss for other medical conditions In some cases, particularly where obesity poses immediate health risks (such as severe type 2 diabetes or cardiovascular disease), the benefits of weight loss may outweigh the potential gallstone risks

Always consult a qualified healthcare provider before starting any new medication or treatment

It is also important to note that semaglutide is not safe during pregnancy

For more information, visit novonordisk.com , Facebook, Twitter, LinkedIn, YouTube

Our comprehensive program includes virtual visits with a licensed provider, personalized health coaching, access to lab testing, and ongoing support